General
Preferred name
GALANTAMINE
Synonyms
Galanthamine hydrobromide ()
GALANTAMINE HYDROBROMIDE ()
Galanthamine HBr ()
Galanthamine ()
Galantamine HBr ()
Galanthamine (hydrobromide) ()
Galantamine (hydrobromide) ()
Galantamine, Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine ()
Gazylan XL ()
Razadyne ()
Reminyl ()
Acumor XL ()
Galsya XL ()
Gatalin XL ()
Luventa XL ()
(-)-galanthamine ()
Reminyl XL ()
Zeebral XL ()
Galzemic XL ()
(-)-galantamine ()
Lotprosin XL ()
NSC-100058 ()
Elmino XL ()
Consion XL ()
Razadyne ER ()
Jilkon hydrobromide ()
Nivalin ()
(-)-galantamine hydrobromide ()
Nivaline ()
Lycoremine hydrobromide ()
Tamilin ()
Galantamine-d3 (hydrobromide) ()
P&D ID
PD001452
CAS
357-70-0
1953-04-4
1551-02-6
1008759-59-8
69353-21-5
2140262-53-7
Tags
natural product
drug
available
Approved by
FDA
First approval
2001
Drug Status
approved
Drug indication
Alzheimer disease
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer's type, but it is only a disease modifying agent that has little effect in altering the course of the underlying process of dementia. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease progresses and there are fewer cholinergic neurons that remain functionally intact.
DESCRIPTION Many alternative stereo forms exist for the structure. The marketed formulation contains galantamine hydrobromide (PubChem CID 121587). (GtoPdb)
DESCRIPTION MAO-A inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Cholinesterase inhibitor (Tocriscreen Total)
Cell lines
1
Organisms
0
Compound Sets
32
AdooQ Bioactive Compound Library
A12483
A10416
Cayman Chemical Bioactives
17559
35247
26103
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL659
CHEMBL1555
ChEMBL Drugs
CHEMBL659
CHEMBL1555
Concise Guide to Pharmacology 2017/18
6693
Concise Guide to Pharmacology 2019/20
6693
Concise Guide to Pharmacology 2021/22
6693
Concise Guide to Pharmacology 2023/24
6693
Drug Repurposing Hub
DrugBank
DB00674
DrugBank Approved Drugs
DB00674
DrugCentral
1272
DrugCentral Approved Drugs
1272
DrugMAP
DMEO794
DrugMAP Approved Drugs
DMEO794
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101393
Guide to Pharmacology
6693
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL659
CHEMBL1555
MedChem Express Bioactive Compound Library
HY-76299
HY-A0009
NCATS Inxight Approved Drugs
0D3Q044KCA
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
galanthamine
Galanthamine-hydrobromide
TargetMol Bioactive Compound Library
T0086
The Spectrum Collection
Tocris Bioactive Compound Library
0686
Tocriscreen Total
External IDs
86
Properties
(calculated by RDKit )
Molecular Weight
287.15
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
1
cLogP
1.85
TPSA
41.93
Fraction CSP3
0.53
Chiral centers
3.0
Largest ring
7.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Acetylcholinesterase inhibitor
Inhibitor
Acetylcholinesterase Inhibitors
Butyrylcholinesterase Inhibitors
Target
Acetylcholinesterase
AChE
Apoptosis
ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG
Cholinesterase (ChE)
nAChR
AChR
AChR,ADC Cytotoxin
Pathway
Neuroscience
Neuronal Signaling
Membrane Transporter/Ion Channel
Primary Target
Cholinesterases
Member status
member
Indication
senile dementia
Therapeutic Class
Parasympathomimetics
Source data